About the Antibody Session
An immunoglobulin (Ig), commonly referred to as an antibody (Ab), is a large, Y-shaped protein that the immune system utilises to recognise and destroy foreign substances like harmful bacteria and viruses. An antigen is a particular pathogen molecule that the antibody detects. These two structures may bind together precisely because each "Y"-shaped tip of an antibody has a paratope (like a lock) that is specific for one particular epitope (like a key) on an antigen. An antibody can either neutralise a pathogen or an infected cell directly through this binding method, or it can mark them for attack by other immune system components (for example, by blocking a part of a virus that is essential for its invasion). The antigen-binding sites at both tips of the antibody are equally diverse, enabling the immune system to recognise millions of distinct antigens. The remaining portion of the antibody, however, is often stable. IgA, IgD, IgE, IgG, and IgM are the only varieties that identify the antibody's class or isotype. Sites involved in interactions with other immune system elements can be found in the constant region at the antibody's trunk. Thus, in addition to some structural characteristics, the class also affects the function that an antibody initiates after attaching to an antigen. Different kinds of antibodies also differ in terms of where in the body they are produced and at what stage of an immune response.
Topics Covered in Antibody
Antibody structure and isotype classes
Antigen recognition and epitope binding
Antibody diversity and affinity maturation
Monoclonal and therapeutic antibodies
Serological testing and antibody detection
Humoral immunity and protective responses
Featured Speakers — Antibody 2027
Speaker lineup for this track will be announced soon.
Browse all speakers →Recent Research Presented at Antibody Sessions
Selected abstracts from this track will be published here.
Related Scientific Sessions at IPHC 2027
Why Attend the Antibody Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Antibody work, reviewed by the scientific committee.
Network Globally
Meet public health researchers, educators, and policy leaders from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Antibody research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join IPHC 2027 for the Antibody track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Antibody Conference 2027 — FAQs
What is the Antibody track at IPHC 2027?
The Antibody track is a dedicated stream within IPHC 2027 covering the latest research, innovation, and best practice in Antibody. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Antibody sessions?
Public health researchers, practitioners, epidemiologists, educators, doctoral students, and policy leaders with an interest in Antibody are all welcome — whether presenting or attending.
Can I present my research in the Antibody track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Antibody sessions?
Yes. IPHC 2027 is a hybrid conference — attend the Antibody track in person in Singapore or join live online, with on-demand access afterward.
Join the IPHC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.
